Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No contest for FDA public relations

This article was originally published in The Tan Sheet

Executive Summary

The House Energy and Commerce Committee calls an FDA campaign to improve its public image "a reckless use of taxpayer dollars." The panel is investigating the award of a sole source contract for the public relations initiative to its probe of "administrative integrity" at the agency. More serious than the campaign's waste of precious resources are "the numerous violations of federal procurement and contracting laws that appear to have occurred," the committee tells HHS Secretary Michael Leavitt in an Oct. 2 letter. The small business designation of Alaska Newspapers, Inc., which was selected to direct the PR campaign, allowed the $300,000 contract to be let without going out to bid. Alaska Newspapers subcontracted the work to Qorvis Communications, which has done PR work for the trade group Pharmaceutical Research and Manufacturers of America. A review of records supplied by the agency in August "suggests that FDA and Qorvis worked together to intentionally circumvent federal contracting regulations," the committee contends. FDA, which has put a hold on all activities under the contract, says Alaska Newspapers certified it would perform at least 51 percent of the work, but an independent investigation was requested Sept. 22

You may also be interested in...

FDA Needs "Public Face" To Improve Reach Of Safety Communications, Cmte. Says

FDA could enhance its stature as a source of product safety information if it put a public face on its risk communications. Christine Bruhn, University of California-Davis, suggested during the advisory panel meeting.

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts